Sanofi tells investors to expect further Consumer Healthcare brand divestments in 2019 as it continues to rationalize its portfolio following the transformational acquisition of Boehringer Ingelheim's OTC business in 2017. As a result of divestments in 2018, as well as a number of seasonal factors, Sanofi reported a 0.6% rise in Consumer Healthcare's sales in Q1.
Sanofi is not done pruning brands from its Consumer Healthcare portfolio as it seeks to better focus its resources on its four core product categories.
Addressing investors on the French firm’s first-quarter earnings call, CEO Olivier Brandicourt said the OTC brand divestments seen in 2018...
In a major milestone for the EU’s pricing and reimbursement landscape, the European Commission has published the first ever, much anticipated, joint clinical assessment report.
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
Weak demand for virus-blocking nasal sprays since the pandemic has left Austrian biotech Marinomed with mounting debts. The company has applied for restructuring proceedings with an Austrian court in an attempt to secure its future.
Perrigo aims its new SolpaOne high-strength paracetamol effervescent at UK pharmacists, who now have expanded powers as part of the UK government's Pharmacy First initiative.
Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.
